Characterization of Toxoplasma gondii glyoxalase 1 and evaluation of inhibitory effects of curcumin on the enzyme and parasite cultures
© Goo et al. 2015
Received: 16 March 2015
Accepted: 14 December 2015
Published: 23 December 2015
The glyoxalase pathway, which includes two enzymes, glyoxalase 1 and 2 (Glo1 and Glo2), is a ubiquitous cellular system responsible for the removal of cytotoxic methylglyoxal produced during glycolysis. Protozoan parasites, including Toxoplasma gondii (T. gondii) tachyzoites, produce methylglyoxal because of increased glycolytic fluxes. A Glo1 inhibitor such as curcumin could be considered a drug candidate for anti-protozoan, anti-inflammatory, and anti-cancer therapy.
The T. gondii Glo1 gene (TgGlo1) was cloned and the recombinant protein was produced. Enzyme kinetics of TgGlo1 and five mutants were evaluated by adding methylglyoxal and glutathione to a reaction mixture. Finally, the inhibitory effects of various concentrations of curcumin on recombinant TgGlo1 were evaluated using in vitro cultures of T. gondii.
Active recombinant TgGlo1 was successfully produced and the active sites (E166 and E251) of TgGlo1 were verified by point mutagenesis. Curcumin at the tested doses inhibited the enzymatic activity of recombinant TgGlo1 as well as the parasitic propagation of in vitro-cultured T. gondii. The Ki and IC50 were 12.9 ± 0.5 μM and 38.3 ± 0.9 μM, respectively.
The inhibitory effect of curcumin on the enzymatic activity of TgGlo1 and parasitic propagation of T. gondii could be explored in the potential development of a potent drug for the treatment of toxoplasmosis. However, considering the fact that curcumin is known to have many effects on other molecules in the micromolar range, further elucidation of curcumin’s direct inhibition of the glyoxalase system of T. gondii will be needed.
KeywordsToxoplasma gondii Glyoxalase pathway Curcumin
Toxoplasma gondii is a major pathogen of a broad range of warm-blooded animals, including humans, livestock, and domestic pets [1, 2]. The parasite is of clinical importance in causing devastating disease in the developing fetus, as well as opportunistic infections in immunocompromised and transplant patients . In human hosts, the parasites differentiate into tachyzoites and bradyzoites, which display distinct physiological features. The dormant bradyzoites show an extremely reduced growth rate, close to complete arrest of the cell cycle, while tachyzoites rapidly duplicate in the acute phase of infection. The tachyzoite stage constitutes an effective pathway for nutrient acquisition and energy metabolism for the parasite.
The glyoxalase pathway is the ubiquitous cellular system responsible for the removal of methylglyoxal, a cytotoxic reactive carbonyl compound produced in many organisms as a consequence of central metabolism [4–6]. During glycolysis, methylglyoxal is produced by imperfect degradation of glucose because of the spontaneous elimination of phosphate from dihydroxyacetone-phosphate or glyceraldehyde-3-phosphate . Plasmodium species, which are apicomplexan parasites closely related to T. gondii, also show increased methylglyoxal production [8, 9]. Therefore, the increased glycolytic fluxes in T. gondii tachyzoites would suggest that these parasites require an efficient detoxification system for removal of harmful methylglyoxal. While there are several reports of studies focusing on the glyoxalase system of Plasmodium species as a potential drug target, no such study has been reported in T. gondii to date .
Curcumin is a polyphenol derivative isolated from the plant Curcuma longa. By interacting with more than 30 proteins, curcumin exhibits anti-inflammatory, anti-oxidant, anti-viral, and anti-infectious activity in extensive studies conducted over the past several decades . Curcumin was recently reported to be a non-glutathione inhibitor of small homodimeric mammalian glyoxalase 1 (Glo1) . In addition, curcumin showed in vitro and in vivo anti-trypanosomal effects in Trypanosoma evansi as well as anti-malarial effects in Plasmodium falciparum cultures and in Plasmodium berghei in vivo [13–15]. In these studies, the effects of curcumin appeared to target the glyoxalase system, as suggested by its inhibition of the enzymatic activities of Glo1 of the Trypanosoma and Plasmodium species.
In the present study, we identified a functional Glo1 of T. gondii (TgGlo1) and evaluated active sites of TgGlo1 by point mutagenesis and enzyme kinetic analysis. In addition, inhibitory effects of curcumin against the enzymatic activity of recombinant TgGlo1 and parasite growth in T. gondii cultures were analyzed.
Parasites and cell cultures
The T. gondii RH and green fluorescent protein-expressing RH (GFP-RH) strains used in this study were maintained in Vero cells and human foreskin fibroblasts (HFFs) at 37 °C and 5 % CO2 in Dulbecco’s modified eagle medium (DMEM, Sigma-Aldrich, St. Louis, MO USA) supplemented with 10 % heat-inactivated fetal bovine serum (FBS).
Cloning of the TgGlo1 gene
Primers used for amplification of TgGlo1 gene and generation of point mutations of TgGlo1
Generation of TgGlo1 point mutants
Mutations of the TgGlo1 gene (E92Q, E166Q, R188E, E251Q, E324Q, E92Q/E324Q, and E166Q/E251Q) were introduced by PCR using Ex Taq polymerase (Takara, Shiga, Japan) with mutated primers (Table 1) and the TgGlo1 gene as a template. The mutant genes were subcloned into the pGEM T-easy vector (Promega, Madison, WI, USA) and subsequently confirmed by sequencing both strands. The mutated genes were subcloned into the pRSETb vector (Invitrogen) for recombinant protein expression.
Expression and protein purification of wild-type and mutants of TgGlo1
The protein expression was performed as previously described by Deponte et al.  with modifications. The pRSETb constructs of the wild-type and mutant TgGlo1 genes were expressed in E. coli strain BL21(DE3)pLysS (Invitrogen). Transformation of the respective plasmid to competent cells was performed before each expression, and the bacteria were precultured overnight at 37 °C. The preculture was added to fresh medium (10 g/L yeast extract, 5 g/L peptone, 10 g/L NaCl, 2 g/L MgSO4 · 7H2O, 10 mM 3-(N-morpholino) propanesulfonic acid (MOPS)/NaOH at pH 7.5, and 100 mg/L ampicillin) and grown at 37 °C. After induction by 0.1 mM isopropyl β-d-1-thiogalactopyranoside and overnight culturing, 3 l of culture cells were harvested by centrifugation (10 min, 12,000 × g) and resuspended in 20 mL of buffer containing 10 mM MOPS/NaOH (pH 7.8), lysozyme, DNase I, and 50 μM phenylmethanesulfonyl fluoride. Then, the resuspended cells were sonicated at 4 °C and centrifuged for 30 min at 12,000 × g. The supernatant was applied to an S-hexylglutathione-agarose column (Sigma-Aldrich), which was equilibrated with buffer containing 10 mM MOPS/NaOH (pH 7.8). After washing with eight column volumes of 10 mM MOPS/NaOH and 200 mM NaCl (pH 7.8), the recombinant enzyme was eluted by three column volumes of 5 mM S-hexylglutathione (pH 7.8). The eluent was loaded onto a nickel-nitrilotriacetic acid column (Qiagen) and eluted with buffer containing 125 mM imidazole (pH 8.0). The purity of rTgGlo1 was confirmed by SDS-PAGE (Additional file 1: Figure S1).
Production of antiserum against TgGlo1
The antiserum specific to TgGlo1 was produced by immunizing five 6-week-old female ICR mice (CLEA Japan, Inc., Tokyo, Japan). The purified rTgGlo1 (200 μg) were emulsified with an equal volume of complete Freund’s adjuvant (Difco Laboratories, Detroit, MI, USA), and then intraperitoneally injected. Two additional boosters with 100 μg of each antigen with incomplete Freund’s adjuvant (Difco) were intraperitoneally administered at 2-week intervals. The mice were bled 2 weeks after the last booster, and serum samples were stored at −30 °C. The specificity of anti-rTgGlo1 serum was evaluated by western blot as shown in Additional file 1: Figure S2.
The calculated concentrations of free GSH after 5 min of preincubation and hemithioacetal were 0.1 mM and 5–500 μM, respectively. After the addition of enzyme, the formation of S-d-lactoylglutathione was measured spectrophotometrically at 240 nm (ε = 3.37 mM−1cm−1). The final assay concentration of the wild-type enzyme and mutants was 5–200 nM. The kinetic data of the initial reaction velocities were plotted according to the Lineweaver-Burk equation using the program SigmaPlot 10.0 (Systat Software Inc., San Jose, CA, USA).
Enzymatic activity inhibition assays of curcumin
The curcumin used for this assay was purchased from Sigma-Aldrich. Enzymatic activity of recombinant TgGlo1 was monitored at 30 °C using a thermostatted spectrophotometer. The TgGlo1 activity was determined at 240 nm by measuring the conversion of the hemithioacetal (the product of methylglyoxal and GSH) into S-d-lactoylglutathione (ε = 3.37 mM−1cm−1). Stock solutions of 10 mM curcumin in assay buffer (50 mM MOPS/NaOH pH 7.0) and less than 10 mM curcumin in methanol were freshly prepared before each experiment. The curcumin was added after the first 4 min of the 5-min preincubation period and the reaction was initiated by adding 5 nM of enzyme.
Growth inhibition assay of curcumin-treated T. gondii
Growth inhibition assay was performed following previously described methods with modifications [17–19]. Inhibition of parasite growth by curcumin was determined by counting the number of vacuoles containing 1, 2, 4, 8, or more than 16 tachyzoites. To investigate the effects of curcumin exposure on parasites, HFFs in 96-well plates were infected for 4 h and then treated with vehicle or decreasing concentrations (25, 15, 10, 5, 2.5, 1, and 0.1 μM) of curcumin for 48 h. Plates were harvested and analyzed by counting the number of vacuoles with different dividing stages of tachyzoites. In addition, in order to determine the 50 % inhibitory concentration (IC50) of curcumin against T. gondii cultures, HFFs infected with T. gondii expressing GFP were counted under a microscope. The IC50 represents the concentration of curcumin that was required for inhibition of 50 % of T. gondii proliferation in the HFF.
This study and all procedures were approved by the Animal Care and Use Committee of Obihiro University of Agriculture and Veterinary Medicine, Japan. The experimental animals were housed, fed, and given clean drinking water in accordance with the stipulated rules for the Care and Use of Research Animals Promulgated by Obihiro University of Agriculture and Veterinary Medicine, Japan.
Results and discussion
Characterization of T. gondii glyoxalase 1
Evaluation of enzyme active sites of T. gondii glyoxalase 1
Enzyme kinetics of recombinant TgGlo1 proteins: a wild type and mutants produced by point-mutagenesis on active sites of TgGlo1
11 ± 2.1
42 ± 5.2
173 ± 8.0
14 ± 2.3
42 ± 2.1
94 ± 3.2
190 ± 5.2
10.0 ± 0.6
38.6 ± 1.5
159 ± 16
76 ± 9
93 ± 4
654 ± 12
254 ± 20
100 ± 17
114 ± 9
1305 ± 38
257 ± 11
Inhibition of T. gondii glyoxalase 1 by curcumin
Curcumin has been reported to have various pharmacological properties including anti-inflammatory, anti-infectious, and anti-carcinogenic . A number of studies have proposed targets for the pharmacological effects including, transcription factors, enzymes, cytokines, and cell receptors. Glo1 has been considered one of the targets of curcumin in previous studies [12, 17]. Curcumin acts by mimicking hemithioacetal, the enediolate reaction intermediate between methylglyoxal and GSH. Therefore, we investigated the inhibitory effects of curcumin on the enzymatic activity of rTgGlo1 by analyzing the steady-state kinetics at decreasing concentrations of substrate and curcumin. As shown in Fig. 3a, Lineweaver-Burk plots indicate competitive inhibition with a constant maximum reaction velocity. The inhibitory effects were consistent in various timings of curcumin addition, from 1 to 4 min (data not shown). Curcumin has a similar structure to hemithioacetal, and it appears that curcumin directly interacts with the active site of TgGlo1. In addition, the Ki value of curcumin against rTgGlo1 was 12.9 ± 0.5 μM, and curcumin inhibition became insignificant at substrate concentrations greater than 125 μM as shown in Additional file 1: Figure S4. Moreover, the enzymatic activity of rTgGlo1 was not completely inhibited by 50 μM curcumin.
Rapidly propagating cells, including cancer cells and protozoan parasites, consume more glucose and have increased glycolytic flux compared to normal cells, resulting in intracellular levels of methylglyoxal that are toxic to the respective cells . Methylglyoxal has been reported to modify the function of distinct proteins including heat shock protein 27, NF-kB, and glyceraldehyde 3-phosphate dehydrogenase in mammalian cells [24, 25]. Modulation of the proteins causes cell death by depletion of ATP, induction of apoptosis, and increases in levels of reactive oxygen species . In order to remove the toxic methylglyoxal, the cells increase expression of Glo1. Therefore, inhibitors of Glo1 have potential as chemotherapeutic agents.
In the current study, a cytosolic TgGlo1 was identified and its active sites (E166 and E251) were verified by point mutagenesis. Curcumin inhibited the enzymatic activity of recombinant TgGlo1 and parasite propagation in cultures of T. gondii. However, considering the fact that curcumin is known to have many effects on other molecules in the micromolar range, further elucidation of curcumin’s direct inhibition of the glyoxalase system of T. gondii will be needed.
This work was supported by a grant from the Global COE Program (J02) and a Grant-in-Aid for Scientific Research (A-22248035), both from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. Y.K.G., M.A.T., and G.O.A. were supported by a research grant fellowship from the Japanese Society for the Promotion of Science (JSPS) for young scientists, Japan.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Dubey JP. History of the discovery of the life cycle of Toxoplasma gondii. Int J Parasitol. 2009;39(8):877–82.PubMedView ArticleGoogle Scholar
- Gebremedhin EZ, Tadesse G. A meta-analysis of the prevalence of Toxoplasma gondii in animals and humans in Ethiopia. Parasit Vectors. 2015;8:291.PubMedPubMed CentralView ArticleGoogle Scholar
- Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15(2):211–22.PubMedView ArticleGoogle Scholar
- Hasim S, Hussin NA, Alomar F, Bidasee KR, Nickerson KW, Wilson MA. A glutathione-independent glyoxalase of the DJ-1 superfamily plays an important role in managing metabolically generated methylglyoxal in Candida albicans. J Biol Chem. 2014;289(3):1662–74.PubMedPubMed CentralView ArticleGoogle Scholar
- Martins AM, Mendes P, Cordeiro C, Freire AP. In situ kinetic analysis of glyoxalase I and glyoxalase II in Saccharomyces cerevisiae. Eur J Biochem. 2001;268(14):3930–6.PubMedView ArticleGoogle Scholar
- Urscher M, Alisch R, Deponte M. The glyoxalase system of malaria parasites--implications for cell biology and general glyoxalase research. Semin Cell Dev Biol. 2011;22(3):262–70.PubMedView ArticleGoogle Scholar
- Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems--role in ageing and disease. Drug Metabol Drug Interact. 2008;23(1–2):125–50.PubMedPubMed CentralGoogle Scholar
- Sousa Silva M, Ferreira AE, Gomes R, Tomas AM, Ponces Freire A, Cordeiro C. The glyoxalase pathway in protozoan parasites. Int J Med Microbiol. 2012;302(4–5):225–9.PubMedView ArticleGoogle Scholar
- Kehr S, Sturm N, Rahlfs S, Przyborski JM, Becker K. Compartmentation of redox metabolism in malaria parasites. PLoS Pathog. 2010;6(12):e1001242.PubMedPubMed CentralView ArticleGoogle Scholar
- Urscher M, More SS, Alisch R, Vince R, Deponte M. Tight-binding inhibitors efficiently inactivate both reaction centers of monomeric Plasmodium falciparum glyoxalase 1. FEBS J. 2012;279(14):2568–78.PubMedView ArticleGoogle Scholar
- Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94.PubMedView ArticleGoogle Scholar
- Santel T, Pflug G, Hemdan NY, Schafer A, Hollenbach M, Buchold M, et al. Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS One. 2008;3(10):e3508.PubMedPubMed CentralView ArticleGoogle Scholar
- Cui L, Miao J. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemother. 2007;51(2):488–94.PubMedPubMed CentralView ArticleGoogle Scholar
- Gressler LT, Oliveira CB, Coradini K, Rosa LD, Grando TH, Baldissera MD, et al. Trypanocidal activity of free and nanoencapsulated curcumin on Trypanosoma evansi. Parasitology. 2015;142(3):439–48.PubMedView ArticleGoogle Scholar
- Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Commun. 2005;326(2):472–4.PubMedView ArticleGoogle Scholar
- Deponte M, Sturm N, Mittler S, Harner M, Mack H, Becker K. Allosteric coupling of two different functional active sites in monomeric Plasmodium falciparum glyoxalase I. J Biol Chem. 2007;282(39):28419–30.PubMedView ArticleGoogle Scholar
- Urscher M, Przyborski JM, Imoto M, Deponte M. Distinct subcellular localization in the cytosol and apicoplast, unexpected dimerization and inhibition of Plasmodium falciparum glyoxalases. Mol Microbiol. 2010;76(1):92–103.PubMedView ArticleGoogle Scholar
- Saleh A, Friesen J, Baumeister S, Gross U, Bohne W. Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases. Antimicrob Agents Chemother. 2007;51(4):1217–22.PubMedPubMed CentralView ArticleGoogle Scholar
- Dzitko K, Paneth A, Plech T, Pawelczyk J, Weglinska L, Paneth P. Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis. Antimicrob Agents Chemother. 2014;58(12):7583–5.PubMedPubMed CentralView ArticleGoogle Scholar
- Himo F, Siegbahn PE. Catalytic mechanism of glyoxalase I: a theoretical study. J Am Chem Soc. 2001;123(42):10280–9.PubMedView ArticleGoogle Scholar
- Richter U, Krauss M. Active site structure and mechanism of human glyoxalase I-an ab initio theoretical study. J Am Chem Soc. 2001;123(29):6973–82.PubMedView ArticleGoogle Scholar
- Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci. 2005;1056:206–17.PubMedView ArticleGoogle Scholar
- de Arriba SG, Stuchbury G, Yarin J, Burnell J, Loske C, Munch G. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells--protection by carbonyl scavengers. Neurobiol Aging. 2007;28(7):1044–50.PubMedView ArticleGoogle Scholar
- Lee CC, Lee BH, Wu SC. Actinidia callosa peel (kiwi fruit) ethanol extracts protected neural cells apoptosis induced by methylglyoxal through Nrf2 activation. Pharm Biol. 2014;52(5):628–36.PubMedView ArticleGoogle Scholar
- Sakamoto H, Mashima T, Yamamoto K, Tsuruo T. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J Biol Chem. 2002;277(48):45770–5.PubMedView ArticleGoogle Scholar
- Morin D, Barthelemy S, Zini R, Labidalle S, Tillement JP. Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation. FEBS Lett. 2001;495(1–2):131–6.PubMedView ArticleGoogle Scholar